Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNV1521 + trastuzumab deruxtecan
- Development stage
- Unknown
- Lead developer
- Synnovation Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SNV1521 + trastuzumab deruxtecan is an experimental combination regimen under investigation for advanced solid tumors. Trastuzumab deruxtecan is an antibody-drug conjugate consisting of a humanized anti-HER2 IgG1 monoclonal antibody (trastuzumab) covalently linked to the topoisomerase I inhibitor deruxtecan (DXd) via an enzymatically cleavable peptide-based linker. In this combination, SNV1521 (exact modality not detailed in search) is being studied alongside trastuzumab deruxtecan for potential synergistic antineoplastic effects. Trastuzumab deruxtecan works by binding to HER2 on cancer cells, leading to internalization and lysosomal cleavage to release DXd, which induces DNA damage and cell death in HER2-expressing tumors. SNV1521 is a separate agent in early phase evaluation, and the combination is currently being studied for safety and preliminary efficacy in solid malignancies[1].
- Other names
- fam-trastuzumab deruxtecan-nxkitrastuzumab deruxtecanT-DXd
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SNV1521 + trastuzumab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNV1521 + trastuzumab deruxtecan.